Recent developments in the therapy of irritable bowel syndrome

Expert Opinion on Investigational Drugs

Volumn 17, Issue 2, 2008, Pages 117-130

  Saad, Richard J ^a   Chey, William D ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Antibiotic; Antidepressant; Chloride channel; Corticotropin releasing hormone; Guanylate cyclase c; Irritable bowel syndrome; Pharmacotherapy; Probiotic; Serotonin

Indexed keywords

ALOSETRON; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; CITALOPRAM; CROFELEMER; DESIPRAMINE; DICYCLOVERINE; DIPHENOXYLATE; DULOXETINE; GUANYLATE CYCLASE ACTIVATOR; GW 876008; HYOSCYAMINE; IMIPRAMINE; LAXATIVE; LOPERAMIDE; LUBIPROSTONE; MELATONIN; OTILONIUM BROMIDE; PLACEBO; PROBIOTIC AGENT; RAMOSETRON; RENZAPRIDE; RIFAXIMIN; SEROTONIN AGONIST; SOLABEGRON; SPASMOLYTIC AGENT; TEGASEROD; TIANEPTINE; UNINDEXED DRUG; VENLAFAXINE; 4 AMINOBUTYRIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOTROPIN RELEASING FACTOR; DRUG DERIVATIVE; HORMONE RECEPTOR; IMMUNOLOGIC FACTOR; MOTILIN RECEPTOR; NEUROPEPTIDE RECEPTOR; OPIATE RECEPTOR; PREGABALIN; SEROTONIN RECEPTOR AFFECTING AGENT; TACHYKININ RECEPTOR; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; AUTONOMIC NERVOUS SYSTEM; BIFIDOBACTERIUM LONGUM INFANTIS; BLOATING; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEFECATION DISORDER; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ESCHERICHIA COLI; GASTROINTESTINAL MOTILITY DISORDER; HEADACHE; HUMAN; INTESTINE INNERVATION; IRRITABLE COLON; ISCHEMIC COLITIS; LABORATORY TEST; LOW DRUG DOSE; MAJOR DEPRESSION; MENTAL STRESS; NAUSEA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CORTICOTROPIN-RELEASING HORMONE; GAMMA-AMINOBUTYRIC ACID; HUMANS; IMMUNOLOGIC FACTORS; IRRITABLE BOWEL SYNDROME; LAXATIVES; MELATONIN; PARASYMPATHOLYTICS; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, NEUROPEPTIDE; RECEPTORS, OPIOID; RECEPTORS, TACHYKININ; SEROTONIN AGENTS;

EID: 39049146162     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.2.117     Document Type: Review

References (116)

1. Guilera M, Balboa A, Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol 2005;100(5):1174-84.
2. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130(5):1480-91
3. Drossman DA, Morris CB, Hu Y, et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology 2005;128(3):580-9
4. Mearin F, Baro E, Roset M, et al. Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability. Am J Gastroenterol 2004;99(1):113-21
5. Camilleri M. Motor function in irritable bowel syndrome. Can J Gastroenterol 1999; 13(Suppl A):8A-11A
6. Quigley EM. Disturbances of motility and visceral hypersensitivity in irritable bowel syndrome: biological markets or epiphenomenon. Gastroenterol Clin North Am 2005;34(2):221-33, vi
7. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001;48(1):14-9
8. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973;14(2):125-32
9. Whitehead WE, Holtkotter B, Erick P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990;98(5 Pt 1): 1187-92
10. Nozu T, Kudaira M, Kitamori S, Uehara A. Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome. J Gastroenterol. 2006;41(3):217-22
11. Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109(1):40-52
12. Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity and predictive values of pain sensory thresholds. Gastroenterology 2002; 122(7):1771-7
13. Drewes AM, Petersen P, Rossel P, et al. Sensitivity and distensibility of the rectum and sigmoid colon in patients with irritable bowel syndrome. Scand J Gastroenterol 2001;36(8):827-32
14. Lawal A, Kern M, Sidhu H, et al. Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology 2006,130(1):26-33
15. Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med 1999; 107(5A):41S-50S
16. Ohman L, Simren M. New insights info the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis 2007;39(3):201-15
17. Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 2007;19(Suppl 2):25-31
18. Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation - and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006;130(1):34-43
19. Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3(4):349-57
20. Gupta V, Sheffield D, Verne GN. Evidence for autonomic dysregulation in the irritable bowel syndrome. Dig Dis Sci 2002;47(8):1716-22
21. van Orshoven NP, Andriesse GI, van Schelven LJ, et al. Subtle involvement of the parasympathetic nervous system in patients with irritable bowel syndrome. Clin Auton Res 2006;16(1):33-9
22. Blackshaw LA, Brookes SJ, Grundy D, Schemann M. Sensory transmission in the gastrointestinal tract. Neurogastroenterol Motil 2007;19(1 Suppl):1-19
23. Bueno L, de Ponti F, Fried M, et al. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. Neurogastroenterol Motil 2007;19(1 Suppl):89-119
24. Hobson AR, Aziz Q. Brain imaging and functional gastrointestinal disorders: has it helped our understanding? Gut 2004;53(8):1198-206
25. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003;124(6):1662-71
26. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome - a meta-analysis. Am J Gastroenterol 2006;101(8):1894-9; quiz 942
27. Marshall JK, Thabane M, Borgaonkar MR, James C. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 2007;5(4):457-60
28. Soyturk M, Akpinar H, Gutler O, et al. Irritable bowel syndrome in persons who acquired trichinellosis. Am J Gastroenterol 2007;102(5):1064-9
29. Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999;44(3):400-6
30. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47(6):804-11
31. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126(3):693-702
32. Gonsalkorale WM, Perrey C, Pravica V, et al. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003;52(1):91-3
33. van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005; 100(11):2510-6
34. Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006;130(2):304-11
35. Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005;100(2):373-82
36. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007;133(1):24-33
37. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95(12):3503-6
38. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004;292(7):852-8
39. Tack J, Fried M, Houghton LA, et al. Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. Aliment Pharmacol Ther 2006;24(2):183-205
40. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000;133(2):136-47
41. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15(3):355-61
42. Lesbros-Pantoflickova D, Michetti P, Fried M, et al. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;20(11-12):1253-69
43. Schoenfeld P. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work. Gastroenterol Clin North Am 2005;34(2):319-35, viii
44. Mearin F. Pharmacological treatment of the irritable bowel syndrome and other functional bowel disorders. Digestion 2006;73(Suppl 1):28-37
45. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125(1):19-31
46. Abdul-Baki H, El Zababi LMN, El Hajj II, et al. A randomized double-blind placebo-controlled trial of imipramine in patients with irritable bowel syndrome (IBS). Am J Gastroenterol 2006;101(Suppl 2):S479 (Abstract)
47. Masand PS, Gupta S, Schwartz TL, et al. Paroxetine in patients with irritable bowel syndrome: a pilot open-label study. Prim Care Companion J Clin Psychiatry 2002;4(1):12-6
48. Wang WA, Qian JM, Pan GZ. Treatment of refractory irritable bowel syndrome with subclinical dosage of antidepressants. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2003;25(1):74-8
49. Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004;99(5):914-20
50. Masand PS, Gupta S, Schwartz TL, et al. Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study. Prim Care Companion J Clin psychiatry 2005;7(4):162-6
51. Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006;55(8):1095-103
52. Chial HJ, Camilleri M, Ferber I, et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003;1(3):211-8
53. Pharmos. Available from: URL: www.pharmoscorp.com/development/ tianeptine.html
54. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003;15(1):79-86
55. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004;(2)
56. Chey WD, Pare P, Viegas A, et al. Tegaserod improves multiple symptoms in women with mixed/alternating bowel habits as well as those with IBS-C. Gastroenterology 2006;130(4 Suppl 2)A-26 (Abstract)
57. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional G1 disorders. Gastroenterology 2007;132(1):397-414
58. Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004;99(11):2195-203
59. Chang L, Chey WD, Harris L, et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006;101(5):1069-79
60. Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007;102(8):1709-19
61. Song GH, Leng PH, Gwee KA, et al. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005;54(10):1402-7
62. Lu WZ, Gwee KA, Moochhalla S, Ho KY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2005;22(10):927-34
63. Saha L, Malhotra S, Rana S, et al. A preliminary study of melatonin in irritable bowel syndrome. J Clin Gastroenterol. 2007;41(1):29-32
64. Crowell MD, Harris LA, DiBaise JK, Olden KW. Activation of type-2 chloride channels: a novel therapeutic target for the treatment of chronic constipation. Curt Opin Investig Drugs 2007;8(1):66-70
65. Lacy BE, Campbell Levy L. Lubiprostone: a chloride channel activator. J Clin Gastroenterol 2007;41(4):345-51
66. Johanson JF, Panas R, Holland PC, Ueno R. A dose-ranging, double-blind, placebo-controlled of lubiprostone in subjects with irritable bowel syndrome and constipation (c-IBS). Gastroenterology 2006;130(4 Suppl 2) A-25 (Abstract)
67. Drossman DA, Chey WD, Panas R, et al. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two, twelve-week, randomized, placebo-controlled, double-blind trials. Gastroenterology 2007;132(4 Suppl 2):P-90 (Abstract)
68. Forte LR. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul Pept 1999;81(1-3):25-39
69. Andersen V, Busciglio I, Grudell A, et al. Eacts of a novel, first-in-class guanylate cyclase-c activator, linaclotide acetate (Md-1100), on gastrointestinal and colonic transit and bowel habits in patients with constipation-predominant irritable bowel syndrome (c-IBS). Gastroenterology 2007;132(4 Suppl 2):A-82 (Abstract)
70. Lembo AJ, Rosenbaum DP, Chey WD, Drossman DA. Safety and efficacy of crofelemer in patients with diarrhea predominant irritable bowel syndrome (IBS-D). Gastroenterology 2007;132(4 Suppl 2)A-141 (Abstract)
71. Quigley EM, Devane J, Young D, Butler J. A randomized, double-blind, placebo-controlled study of R-verapamil in non-cohstipated irritable bowel syndrome. Am J Gastroenterol 2007;102(S2):S502 (Abstract)
72. Delvaux M, Beck A, Jacob J, et al. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004;20(2):237-46
73. Karver S, Israel RJ. Methylnaltrexone improves opioid-induced constipation and reduces laxative use in patients with advanced illness. Gastroenterology 2007;132(4 Suppl 2):A-478 (Abstract)
74. Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction - a 21-day treatment-randomized clinical trial. J Pain 2005;6(3):184-92
75. Kelleher D, Johanson J, Pobiner B, et al. Alvimopan, a, peripherally acting mu-opioid receptor (PAM-OR) antagonist - a study in patients with chionic idiopathic constipation (CIC) not taking opioid medication. Am J Gastroenterol 2006;101(9):s480 (Abstract)
76. McCallum RW, Cynshi O. Efficacy of mitemcinal, a motilin-agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy. a randomized, multi-center, placebo-controlled trial. Aliment Pharmacol Ther 2007;26(1):107-16
77. Ozaki K, Sudo H, Muramatsu H, et al. Mitemcinal (GM-611), an orally active motilin receptor agonist, accelerates colonic motility and bowel movement in conscious dogs. Inflammopharmacology 2007;15(1):36-42
78. Sudo H, Ozaki K, Muramatsu H, et al. Mitemcinal (GM-611), an orally active motilin agonist, facilitates defecation in rabbits and dogs without causing loose stools. Neurogastroenterol Motil 2007;19(4):318-26
79. Posserud I, Stotzer PO, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007;56(6):802-8
80. Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2007;25(11):1271-81
81. Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49(3):467-84
82. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006;145(8):557-63
83. Salix. Available from: URL: www.salix.com/news/stories/20070905.aspx
84. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128(3):541-51
85. Brenner DM, Moeller M, Chey WD, Schoenfeld P. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2007;102(Suppl 2):S500 (Abstract)
86. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101(7):1581-90
87. Dunlop SP, Jenkins D, Neal KR, et al. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003;18(1):77-84
88. Stefanini GF, Saggioro A, Alvisi V, et al. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Scand J Gastroenterol 1995;30(6):535-41
89. Lunardi C, Bambara LM, Biasi D, et al. Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance. Clin Exp Allergy 1991;21(5):569-72
90. Camilleri M, McKinzie S, Fox J, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004;2(10):895-904
91. Astellas. Available from: URL: www.astellas.com/global/ir/library/pdf/ rd2006_1_eg.pdf
92. Theravance. Available from: URL: ir.theravance.com/ReleaseDetail. cfm?ReleaseID=250925
93. Dynogen. Available from: URL: www.dynogen.com/pipeline_gi.htm
94. Tache Y, Monnikes H, Bonaz B, Rivier J. Role of CRF in stress-related alterations of gastric and colonic motor function. Ann NY Acad Sci 1993;697:233-43
95. Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998;42(6):845-9
96. Sagami Y, Shimada Y, Tayama J, et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004;53(7):958-64
97. Lecci A, Valenti C, Maggi CA. Tachykinin receptor antagonists in irritable bowel syndrome. Curr Opin Investig Drugs 2002;3(4):589-601
98. Tousignant-Laflamme Y, Goffaux P, Bourgault P, Marchand S. Different autonomic responses to experimental pain in IBS patients and healthy controls. J Clin Gastroenterol 2006;40(9):814-20
99. Ng C, Malcolm A, Hansen R, Kellow J. Feeding and colonic distension provoke altered autonomic responses in irritable bowel syndrome. Scand J Gastroenterol 2007;42(4):441-6
100. Robert JJ, Elsenbruch S, Orr WC. Sleep-related autonomic disturbances in symptom subgroups of women with irritable bowel syndrome. Dig Dis Sci 2006;51(12):2121-7
101. Camilleri M, Kim DY, McKinzie S, et al. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003;1(2):111-21
102. Allergan. Available from: URL: www.allerganclinicaltrials.com/ongoing/ stomach_intestine_conditions.htm
103. Quigley EM, Devane J, Young D, Butler J. A randomized, controlled. double-blind trial of s-pindolol in irritable bowel syndrome (IBS). Am J Gastroenterol 2007;102(S2):S501 (Abstract)
104. Leventer S, Kucharik R, Keogh JC, et al. The potential of dextofisopam for treatment of irritable bowel syndrome and inflammatory bowel disease. Am J Gastroenterol 2004;99(s10):s279 (Abstract)
105. Leventer S, Raudibaugh K, Frissora C, et al. The safety and efficacy of dextofisopam in patients with diarrhea-predominant or alternating irritable bowel syndrome. Gastroenterology 2005;128(4 Suppl 2):A-94 (Abstract)
106. Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg 2007;105(6):1805-15
107. Diop L, Raymond F, Fargeau. H, et al. Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat. J Pharmacol Exp Ther 2002;302(3):1013-22
108. Eutamene H, Coelho AM. Theodorou V, et al. Antinociceptive effect of pregabalin in septic shock-induced rectal hypersensitivity in rats. J Pharmacol Exp Ther 2000;295(1):162-7
109. Houghton LA, Fell C, Whorwell PJ, et al. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007;56(9):1218-25
110. Chugai. Available from: URL: www.chugai-pharm.co.jp/pdf/pipeline/ english/070731 ePipeline.pdf
111. Clinical trials. Available from: URL: ctinicaltrials.gov/ct/show/ NCT00401258?order=1
112. Bristol-Myers Squibb. Available from: URL: ctr.bms.com/ctd/ InitTrialDetailAction.do?pnum=CN148013%20ST
113. ClaxoSmithKline. Available from: URL: www.gsk.com/investors/ pp_pipeline_standard.htm
114. Gastrotech. Available from: URL: www.gastrotechpharma.com/ Product_PipeLine.htm
115. Avera. Available fiom: URL: www.averapharm.com/AV608.html
116. Sanofi aventis Available from: URL: en.sanofi-aventis.com/rd/portfolio/ p↠∝rtfolioℕc.asp